Nasdaq retreats as technology stocks lose favor
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall St set for muted open as tech wobble persists; Tesla gains
- Oil heads for weekly gain with focus on Middle East supply
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Vertiv shares fall on analyst downgrades and options bets
- European stocks rise, dollar set for weekly loss after yields drop
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Mizuho Securities Reiterates Buy Rating on Pfizer (PFE)
November 12, 2020 8:22 AM ESTMizuho Securities analyst Vamil Divan reiterated a Buy rating and $44.00 price target on Pfizer (NYSE: PFE) following the company's COVID-19 vaccine data released on Monday. The COVID-19 data was eagerly anticipated by investors for obvious reasons.
The company has already secured commitments from... More
Pfizer (PFE) Reports Positive Results from Fifth Phase 3 Trial of Abrocitinib
November 11, 2020 6:46 AM ESTPfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE REGIMEN study. This 52-week study investigated abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200mg. Patients were randomized... More



